Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials.
Federico Coccolini, Matteo Nardi, Giulia Montori...
https://pubmed.ncbi.nlm.nih.gov/29413875/Actively Recruiting
Led by National Research Oncology and Transplantology Center, Kazakhstan · Updated on 2025-05-09
160
Participants Needed
1
Research Sites
48 weeks
Total Duration
Gastric cancer is a common and serious disease, ranking as the fifth most frequent cancer worldwide and the third leading cause of cancer-related deaths. Patients with locally advanced gastric cancer often face the challenge of peritoneal carcinomatosis PC, a condition occurring in 60% of cases after surgery and linked to poor outcomes. Researchers are evaluating whether adding a new preoperative treatment called pressurized intraperitoneal aerosolized chemotherapy PIPAC can reduce the occurrence of PC compared to standard treatment alone. The study compares two groups one receiving PIPAC with the chemotherapy drugs cisplatin and doxorubicin before standard perioperative chemotherapy FLOT regimen and surgery including gastrectomy with lymphadenectomy the other group is a retrospective cohort receiving only the standard chemotherapy and surgery. PIPAC delivers chemotherapy as an aerosol directly to the peritoneal surface, aiming to penetrate tumor implants more deeply while minimizing side effects. Participants will be monitored through scheduled assessments, including evaluations of survival rates, disease progression, quality of life using the EORTC QLQ-C30 questionnaire, and safety events. The main outcome is the incidence of peritoneal carcinomatosis at 12 and 24 months after surgery. Secondary outcomes include overall and disease-free survival, adverse events, and pathological response. The study begins in January 2025 and will follow participants over multiple years to gather these results.
CONDITIONS
Preventive Use of PIPAC in Locally Advanced Gastric Cancer.
A
Altay Kerimkulov, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Research Oncology and Transplantology Center, Kazakhstan
Lead Sponsor
Ministry of Science and Higher Education of the Republic of Kazakhstan
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Before perioperative chemotherapy
Participants in the intervention group receive preventive pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin before starting perioperative chemotherapy.
1 visit for PIPAC procedure
Duration - Duration of chemotherapy cycles plus surgery period
Participants receive perioperative chemotherapy with the FLOT regimen followed by gastrectomy with D2 lymphadenectomy.
Multiple visits for chemotherapy and surgery as part of routine care
Duration - Up to 5 years after surgery
Participants are monitored for survival, disease recurrence, adverse events, and quality of life after surgery.
Visits at 30 days, 90 days, 3, 6, 9, 12, 18, 24 months, and annually up to 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Federico Coccolini, Matteo Nardi, Giulia Montori...
https://pubmed.ncbi.nlm.nih.gov/29413875/Salah-Eddin Al-Batran, Sylvie Lorenzen
https://pubmed.ncbi.nlm.nih.gov/28501086/Altay Kerimkulov, Talgat Uskenbayev, Tomiris Sarina...
https://pubmed.ncbi.nlm.nih.gov/41218205/Olivia Sgarbura, Clarisse Eveno, Mohammad Alyami...
https://pubmed.ncbi.nlm.nih.gov/35602919/J S Macdonald, S R Smalley, J Benedetti...
https://pubmed.ncbi.nlm.nih.gov/11547741/Eddy Cotte, Guillaume Passot, François-Noël Gilly...
https://pubmed.ncbi.nlm.nih.gov/21160814/National Research Oncology and Transplantology Center, Kazakhstan
Lead Sponsor
Ministry of Science and Higher Education of the Republic of Kazakhstan
Collaborating Sponsor